logo

Bioxcel Therapeutics, Inc. (BTAI)



Trade BTAI now with
  Date
  Headline
7/5/2022 7:22:57 AM BioXcel Therapeutics Appoints Michael Miller To Board
4/19/2022 7:26:29 AM BioXcel Therapeutics Announces $260 Mln Strategic Financing With Oaktree And Qatar Investment Authority
4/6/2022 7:27:01 AM BioXcel Therapeutics: FDA Approves IGALMI Sublingual Film
12/1/2021 7:37:02 AM BioXcel Therapeutics Extends FDA Review Period Of NDA For BXCL501 By Three Months To April 5, 2022
8/10/2021 7:30:15 AM BioXcel Therapeutics Q2 Net Loss Of $27.6 Mln Vs Loss Of $21.4 Mln Last Year
5/19/2021 7:26:20 AM BioXcel: FDA Accepts BXCL501 NDA Filing For Acute Treatment Of Agitation Associated With Schizophrenia& Bipolar Disorder
3/15/2021 7:12:35 AM BioXcel's BXCL501 Gets FDA Breakthrough Therapy Designation For Acute Treatment Of Agitation Associated With Dementia
3/11/2021 7:14:58 AM BioXcel Submits NDA For BXCL501 For Acute Treatment Of Agitation Associated With Schizophrenia And Bipolar Disorders
1/5/2021 7:13:48 AM BioXcel Says BXCL501 Meets Endpoints In TRANQUILITY Phase 1b/2 Study For Acute Treatment Of Agitation In Dementia